# A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors

Source: https://onco.cc/trials/nct05315167/  
OnCo record `nct05315167` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of PRJ1-3024 in advanced solid tumours, run by Zhuhai Yufan Biotechnologies Co., Ltd, now recruiting.

## Summary

A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05315167 by Zhuhai Yufan Biotechnologies Co., Ltd, with 267 participants planned, started 2022-05-30 and due to reach its primary completion in 2027-05-15. Interventions recorded: PRJ1-3024.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05315167
- Phase: 1/2
- Setting: A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Prime Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors
- Sponsor: Zhuhai Yufan Biotechnologies Co., Ltd
- Enrolled: 267

## Sources

- ClinicalTrials.gov NCT05315167: https://clinicaltrials.gov/study/NCT05315167

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Zhuhai Yufan Biotechnologies](https://onco.cc/companies/zhuhai-yufan-biotechnologies/)

---
JSON: https://onco.cc/api/v1/entities/nct05315167.json